Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway

Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway

As a newly approved oral hypoglycaemic agent, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin, which is derived from the natural product phlorizin can effectively reduce blood glucose. Recent clinical studies have found that dapagliflozin alleviates non-alcoholic fatty liver disea...

Full description

Bibliographic Details
Main Authors: Liuran Li, Qinghua Li, Wenbin Huang, Yibing Han, Huiting Tan, Min An, Qianru Xiang, Rui Zhou, Li Yang, Yanzhen Cheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Pharmacology
Subjects:
NAFLD
AMPK
mTOR
autophagy
dapagliflozin
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.589273/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.589273/full

Similar Items